RMD

Business profile & competitive position

ResMed Inc. operates in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. The company is a global developer and marketer of digital-health and cloud-connected medical devices centered on sleep and breathing health. Its product lines include CPAP, APAP, bilevel, and ventilation devices; masks; diagnostics; dental devices; and connected-care software. ResMed also sells cloud-based Residential Care Software to home medical equipment, home health, hospice, skilled nursing, and senior living providers, and it distributes products in more than 140 countries through subsidiaries and independent distributors.

The financial fingerprint of this model is strong. ResMed reports a net margin of 26.9% and a return on equity of 23.9%. Those figures sit well above what is typical for a commodity medical-device supplier, and they are consistent with a business that benefits from recurring mask and accessory revenue, software subscriptions, and a large installed base of connected devices. A beta of 0.75 also points to a relatively lower-volatility, defensive cash-flow profile within Healthcare, which fits a recurring-revenue medical-supply story rather than a speculative development-stage name.

Financial posture

ResMed currently carries a market capitalization of $33.5 billion and trades at a price-to-earnings ratio of 22.1. Against a 26.9% net margin and 23.9% ROE, that valuation places it in the territory of a profitable, large-cap medtech name rather than a high-multiple growth stock. The current share price is $230.81, with the 50-day EMA at $222.21, and the RSI at 62.1, which is approaching—but still below—traditional overbought territory.

The combination of a 22.1 P/E and a 26.9% net margin suggests the market is paying for quality and consistency, not just top-line growth. The beta of 0.75 reinforces the impression of an equity that has historically moved less dramatically than the broad market, a characteristic that generally aligns with steady medical-device cash flows. That profile does not, on its own, indicate that the stock is cheap or expensive; it simply frames ResMed as a highly profitable, lower-beta large-cap Healthcare name.

Strategic priorities & outlook

ResMed’s most recent SEC 10-K filing outlines a strategy built on three linked priorities: deepening the core sleep-apnea franchise, accelerating market growth through disease awareness, and extending the digital-health ecosystem into the home.

On the core franchise, the company is integrating artificial intelligence and machine learning into its devices and masks, simplifying care pathways, and expanding home diagnostics through offerings such as NightOwl and the VirtuOx IDTF acquisition. For market expansion, ResMed is targeting awareness and education efforts at patients, physicians, and special-interest groups for sleep apnea, COPD, and related comorbidities. The company is also moving into adjacent breathing and sleep-health categories, including COPD, neuromuscular disease, and restless legs syndrome—the last of which follows the Noctrix acquisition.

Operationally, ResMed reports two segments: Sleep and Breathing Health, and Residential Care Software. In fiscal 2026, devices generated roughly 51% of net revenue, masks/diagnostics/accessories contributed roughly 37%, and software accounted for roughly 12%. The filing also notes that in June 2026 ResMed agreed to sell its MatrixCare business for $490 million in cash, a deal expected to close in the first quarter of fiscal 2027, with the goal of sharpening focus on core sleep, breathing, and connected home-based healthcare. As of the filing, ResMed employed approximately 11,370 people, had more than 35 million cloud-connected devices on AirView, and had more than 12 million patients registered on myAir.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies company with global distribution, ResMed faces macro exposures that are standard for the device industry. Regulatory risk is central: FDA clearances, enforcement actions, product recalls, and changes to device classification can alter both costs and market access. Reimbursement risk is equally important, because a meaningful share of end-user demand is tied to third-party payers, including Medicare and Medicaid, where coverage or payment-rate changes can ripple through volumes and pricing.

Trade policy and supply-chain issues also matter. CPAP and ventilation devices rely on semiconductors, motors, and other electronic components that can be affected by tariffs, export controls, or shortages. Because ResMed sells in more than 140 countries, foreign exchange risk is built into the revenue stream, with a stronger U.S. dollar pressuring translated overseas sales and vice versa. Finally, headline developments in related therapeutic areas—such as the rise of GLP-1 obesity therapies—can influence investor sentiment around sleep-apnea treatment demand, even if the near-term operational impact is still unfolding.

Recent developments

Several recent headlines frame the narrative heading into the next earnings report. On October 1, 2026, ResMed announced via GlobeNewswire that it will report first quarter fiscal 2027 earnings on October 29, 2026. On September 22, 2026, DefenseWorld reported that ResMed is targeting 12%-14% EPS growth and that GLP-1 patients are lifting sleep-therapy demand. That story aligns with the company’s broader awareness-and-education strategy and its effort to frame sleep apnea as part of a larger cardiometabolic care pathway.

On October 11, 2026, two items appeared. SeekingAlpha.com included ResMed in its “Top 50 High-Quality Dividend Growth Stocks For October 2026” list, while DefenseWorld reported that ResMed’s CEO sold $1,129,613.03 in company stock. Insider sales are a routine disclosure item and do not, by themselves, signal a change in corporate fundamentals, but they are part of the near-term tape that traders and investors will consider alongside earnings on October 29.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, ResMed has beaten earnings estimates seven times, for an 88% beat rate, with an average earnings surprise of 3%. The average five-day post-earnings price move across those quarters is 0.24%, classified as flat, which means the stock has not shown a durable directional drift after reporting.

The last four quarterly reports illustrate a “sell the news” pattern that is worth watching. On August 6, 2026, ResMed reported EPS of $2.95 against an estimate of $2.89, a 2.1% beat, yet the stock fell 5.06% the next day and rose 1.57% over the next five days. On April 30, 2026, the company earned $2.86 versus a $2.80 estimate, another 2.1% beat, but the stock dropped 4.11% the next day and 3.24% over the following five days. The January 29, 2026 report delivered $2.81 versus $2.74, a 2.6% beat, with a muted next-day gain of 0.27% and a five-day gain of 3.66%. The October 30, 2025 report produced $2.55 versus $2.51, a 1.6% beat, and the stock fell 2.13% the next day and 1.03% over five days.

That history suggests the market’s real expectation can run ahead of the published consensus, so a headline beat is not automatically rewarded. The next report is scheduled for October 29, 2026, after the close, with a consensus EPS estimate of $2.68. With the stock at $230.81 and RSI at 62.1, the setup is one where realized results will be judged both against the $2.68 estimate and against the unofficial consensus embedded in the price.

For a deeper dive into how sell-side models, valuation work, and risk factors are currently calibrated, look at the full institutional verdict on RMD before the October 29 report.